Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
EUROPEAN JOURNAL OF NEUROLOGY ; 29:570-570, 2022.
Article in English | Web of Science | ID: covidwho-1965421
4.
IEEE URUCON Conference (IEEE URUCON) ; : 368-371, 2021.
Article in English | Web of Science | ID: covidwho-1819857

ABSTRACT

The differential diagnosis of respiratory diseases is usually a challenge for medical specialists in the first line of care, increased under the current COVID-19 pandemic. A Clinical Decision Support System -CDSS- is being developed using Bayesian Networks - BNs - to help physicians diagnose respiratory diseases, including those related to COVID-19. Network structure has been elicited from expert physicians, and network parameters (diseases prevalence, symptoms, findings, and lab results conditional probabilities) were extracted from relevant bibliography or currently standard global information sources. The CDSS is being tested using case studies taken from real situations, provided and validated by physicians. The resulting system demonstrates the suitability and flexibility of BNs for diagnosis support and healthcare training.

7.
Multiple Sclerosis Journal ; 27(2 SUPPL):797-798, 2021.
Article in English | EMBASE | ID: covidwho-1496057

ABSTRACT

Introduction: Per WHO, >190 million people worldwide have been affected by COVID-19 as of 20-Jul-2021. Although people with MS are not at a higher risk of SARS-CoV-2 infection, factors such as age, comorbidity, MS severity and treatment with DMTs may affect COVID-19 severity and outcomes. Understanding the risks, severity and outcomes of COVID-19 in people with MS receiving DMTs, including anti-CD20 DMTs, is important to healthcare practitioners (HCPs) managing MS. Objectives: To report the characteristics and outcomes of COVID- 19 adverse events (AEs) in relapsing MS (RMS) patients taking ofatumumab enrolled in the ongoing, open-label, long-term extension Phase 3b ALITHIOS study and from post-marketing surveillance of people receiving ofatumumab 20 mg subcutaneously. Methods: Patient demographics, baseline characteristics, incidence of COVID-19 AEs, seriousness category (including hospitalization), severity, outcomes, ofatumumab exposure before the start of infection, and action taken with ofatumumab were assessed. Results: As of 29-Jan-2021, 139/1703 (8.2%) patients enrolled in ALITHIOS (mean±SD age at baseline: 37.7±8.7 years;female, 64%) treated with ofatumumab reported COVID-19 AEs (confirmed: 115 [82.7%];suspected: 24 [17.3%]). Of these, 10 (7.2%) experienced COVID-19 serious AEs and all 10 (7.2%) were hospitalized. Most AEs reported were mild (Grade [G] 1;69 [49.6%]) or moderate (G2;62 [44.6%]) in severity. Severe (G3) and life threatening (G4) AEs were reported in 6 (4.3%) and 2 (1.4%) patients, respectively. One (0.7%) patient (48-year-old at COVID- 19 onset;BMI 28.3 kg/m2;recent MS relapse) with confirmed COVID-19 and pneumonia had a fatal outcome. At data cut-off, most patients (128 [92.1%]) had recovered from COVID-19 AEs;2 (1.4%) were recovering, 4 (2.9%) had recovered with sequelae and 4 (2.9%) had not recovered. COVID-19 AEs led to temporary interruption of ofatumumab in 22 (15.8%) patients. As of 31-Jan- 2021, an additional 28 RMS patients with COVID-19 AEs were identified in the Novartis safety database. Further details to be presented. Conclusions: In ALITHIOS, 139 RMS patients on ofatumumab reported COVID-19 AEs (as of 31-Jan-2021). Most (94%) COVID-19 cases were mild or moderate in severity. There were few hospitalizations but one fatal outcome. At data cut-off, most (92%) patients had recovered/resolved from COVID-19. ALITHIOS data extends the understanding of the long-term safety profile of ofatumumab in people living with MS.

8.
IEEE Access ; 2021.
Article in English | Scopus | ID: covidwho-1447781

ABSTRACT

An accurate analysis of user behaviour in online learning environments is a useful means of early follow up of students, so that they can be better supported to improve their performance and achieve the expected competences. However, that task becomes challenging due to the massive data that learning management systems store and categorise. With the COVID-19 pandemic still on-going, face-to-face learning settings have migrate into online and blended ones, meaning an increase of online students and teachers in need for a tailored and effective support to their needs. A novel unsupervised clustering technique based on the Self-Organizing Map (SOM) artificial neural network model is used in this research to analyse 1,709,189 records of online students enrolled from 2015 to 2019 at Universidad Internacional de La Rioja (UNIR), a fully online Higher Education institution. SOM performs a precise and diverse user clustering based on those records. Results highlight that specific clusters are linked to the intake average profile at the university, with a clear relation between user interaction and a higher performance. Further, results show that, out of a targeted desk research compared to the analysis in this paper, face-to-face and online settings are connected through the methodological approach beyond the technology-based environment, which presents a similar behaviour in both contexts. Author

9.
Neurology ; 96(15 SUPPL 1), 2021.
Article in English | EMBASE | ID: covidwho-1407819

ABSTRACT

Objective: Report characteristics of COVID-19 infections in people with multiple sclerosis (pwMS) receiving subcutaneous 20mg of atumumab, a human anti-CD20 monoclonal antibody, every 4 weeks. Background: A global pandemic of COVID-19 has resulted in over 40 million cases as of 19 October 2020. Risks of COVID-19 in pwMS receiving disease-modifying therapies are of increased interest, but still under investigation. Design/Methods: Demographics, COVID-19 seriousness category, of atumumab treatment duration and action taken with of atumumab, interventions and COVID-19 outcomes were recorded for pwMS in the open-label extension study ALITHIOS or in the post-marketing setting. Results: As of 28 September 2020, 12/1623 pwMS (5/12 females;9/12 white) in the ALITHIOS study were reported to have laboratory-confirmed SARS-CoV-2 infection. Mean age was 37.8 years (median 44 years, range 25-51 years), disease duration 3 to 23 years, and EDSS score 0-5.5. Ofatumumab exposure range was 8.5-13.8 months (n=6 who received of atumumab only in ALITHIOS) and 17.4-44.2 months (n=6 who continued of atumumab from prior trials). One of 12 had COVID-19 seriousness grade 3-A 39 year old white male with bilateral pneumonia requiring hospitalization who recovered with normal follow-up chest X-ray. The remaining 11 cases were non-serious grades 1 or 2: Seven reported as completely recovered, one recovering, two as ongoing and one asymptomatic with SARS-CoV-2 IgM and IgG positive. Six patients were treated with anti-infectives (three received both antivirals and antibacterials and three received antibacterials). Ofatumumab treatment was unchanged in seven and interrupted in four (resumed in three;information not available for one) patients;action unknown in one. To date, no post-marketing COVID-19 cases have been reported. Conclusions: We report 12 cases (11 non-serious;one serious hospitalized for bilateral pneumonia) of laboratory-confirmed SARS-CoV-2 infection in pwMS treated with of atumumab. More surveillance data are needed to determine the risks associated with COVID19 in pwMS treated with of atumumab.

10.
Cogitare Enfermagem ; 25:1-8, 2020.
Article in English | Scopus | ID: covidwho-1090226

ABSTRACT

Objective: To present a brief description of home art therapy techniques as Nursing care for older adults in contingency due to COVID-19. Development: Faced with the pronouncement of the health measures for COVID-19, older adults as the highest risk group require strict adherence to the isolation recommendations, for which some art therapy techniques are proposed as Nursing care, among which drawings, mandalas, painting, collages and mask technique stand out;which can favor the mental health of the older adults at theirnomes, as well as favor cognitive stimulation, mobility and expression of emotions;thus, its benefits involve the physical, social, emotional and spiritual well-being of the older adults. Final considerations: Plastic arts as therapeutic strategies can be incorporated by the nurse in home activities for the older adults, favoring cognitive functions, preventing cognitive deterioration, maintaining mobility, and improving emotional state. © 2020, Universidade Federal do Parana 1. All rights reserved.

SELECTION OF CITATIONS
SEARCH DETAIL